FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225517596> ?p ?o ?g. }

• W4225517596 abstract "Familial partial lipodystrophy (FPLD) is a rare disease characterized by selective loss of peripheral subcutaneous fat, associated with dyslipidemia and diabetes mellitus. Reductions in circulating levels of ANGPTL3 are associated with lower triglyceride and other atherogenic lipids, making it an attractive target for treatment of FPLD patients. This proof-of-concept study was conducted to assess the efficacy and safety of targeting ANGPTL3 with vupanorsen in patients with FPLD.This was an open-label study. Four patients with FPLD (two with pathogenic variants in LMNA gene, and two with no causative genetic variant), diabetes (HbA1c ≥ 7.0 % and ≤ 12 %), hypertriglyceridemia (≥ 500 mg/dL), and hepatic steatosis (hepatic fat fraction, HFF ≥ 6.4 %) were included. Patients received vupanorsen subcutaneously at a dose of 20 mg weekly for 26 weeks. The primary endpoint was the percent change from baseline in fasting triglycerides at Week 27. Other endpoints analyzed at the same time point included changes in ANGPTL3, fasting lipids and lipoproteins, insulin secretion/sensitivity, postprandial lipids, and glycemic changes in response to a mixed meal test, HFF measured by MRI, and body composition measured by dual-energy absorptiometry (DEXA).Baseline mean ± SD fasting triglyceride level was 9.24 ± 4.9 mmol/L (817.8 ± 431.9 mg/dL). Treatment resulted in reduction in fasting levels of triglycerides by 59.9 %, ANGPTL3 by 54.7 %, and in several other lipoproteins/lipids, including very low-density lipoprotein cholesterol by 53.5 %, non-high-density lipoprotein cholesterol by 20.9 %, and free fatty acids (FFA) by 41.7 %. The area under the curve for postprandial triglycerides, FFA, and glucose was reduced by 60 %, 32 %, and 14 %, respectively. Treatment with vupanorsen also resulted in 55 % reduction in adipose tissue insulin resistance index, while other insulin sensitivity indices and HbA1c levels were not changed. Additional investigations into HFF and DEXA parameters suggested dynamic changes in fat partitioning during treatment. Adverse events observed were related to common serious complications associated with diabetes and FPLD. Vupanorsen was well tolerated, and there was no effect on platelet count.Although limited, these results suggest that targeting ANGPTL3 with vupanorsen could address several metabolic abnormalities in patients with FPLD." @default.
• W4225517596 created "2022-05-05" @default.
• W4225517596 creator A5001841202 @default.
• W4225517596 creator A5008732714 @default.
• W4225517596 creator A5009316317 @default.
• W4225517596 creator A5019273939 @default.
• W4225517596 creator A5039463155 @default.
• W4225517596 creator A5045147982 @default.
• W4225517596 creator A5083594961 @default.
• W4225517596 date "2021-12-01" @default.
• W4225517596 modified "2023-10-18" @default.
• W4225517596 title "Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study" @default.
• W4225517596 cites W1967524653 @default.
• W4225517596 cites W2009330135 @default.
• W4225517596 cites W2022725370 @default.
• W4225517596 cites W2028962874 @default.
• W4225517596 cites W2126025827 @default.
• W4225517596 cites W2136226749 @default.
• W4225517596 cites W2154029700 @default.
• W4225517596 cites W2160234571 @default.
• W4225517596 cites W2163235677 @default.
• W4225517596 cites W2261430354 @default.
• W4225517596 cites W2326075804 @default.
• W4225517596 cites W2510339450 @default.
• W4225517596 cites W2528176296 @default.
• W4225517596 cites W2571158149 @default.
• W4225517596 cites W2590460677 @default.
• W4225517596 cites W2607031541 @default.
• W4225517596 cites W2608084845 @default.
• W4225517596 cites W2617605538 @default.
• W4225517596 cites W2618984243 @default.
• W4225517596 cites W2708896703 @default.
• W4225517596 cites W2719913111 @default.
• W4225517596 cites W2740302530 @default.
• W4225517596 cites W2761312904 @default.
• W4225517596 cites W2797973053 @default.
• W4225517596 cites W2891480657 @default.
• W4225517596 cites W2899407995 @default.
• W4225517596 cites W2899710230 @default.
• W4225517596 cites W2906651560 @default.
• W4225517596 cites W2918535553 @default.
• W4225517596 cites W2922289951 @default.
• W4225517596 cites W2944300826 @default.
• W4225517596 cites W2958222855 @default.
• W4225517596 cites W3005016177 @default.
• W4225517596 cites W3008607674 @default.
• W4225517596 cites W3019885136 @default.
• W4225517596 cites W3020893344 @default.
• W4225517596 cites W3035657878 @default.
• W4225517596 cites W3036859000 @default.
• W4225517596 cites W3082366829 @default.
• W4225517596 cites W3119435330 @default.
• W4225517596 cites W3121827512 @default.
• W4225517596 cites W4211034139 @default.
• W4225517596 doi "https://doi.org/10.1186/s12944-021-01589-4" @default.
• W4225517596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34865644" @default.
• W4225517596 hasPublicationYear "2021" @default.
• W4225517596 type Work @default.
• W4225517596 citedByCount "10" @default.
• W4225517596 countsByYear W42255175962022 @default.
• W4225517596 countsByYear W42255175962023 @default.
• W4225517596 crossrefType "journal-article" @default.
• W4225517596 hasAuthorship W4225517596A5001841202 @default.
• W4225517596 hasAuthorship W4225517596A5008732714 @default.
• W4225517596 hasAuthorship W4225517596A5009316317 @default.
• W4225517596 hasAuthorship W4225517596A5019273939 @default.
• W4225517596 hasAuthorship W4225517596A5039463155 @default.
• W4225517596 hasAuthorship W4225517596A5045147982 @default.
• W4225517596 hasAuthorship W4225517596A5083594961 @default.
• W4225517596 hasBestOaLocation W42255175961 @default.
• W4225517596 hasConcept C126322002 @default.
• W4225517596 hasConcept C134018914 @default.
• W4225517596 hasConcept C139572402 @default.
• W4225517596 hasConcept C2776175330 @default.
• W4225517596 hasConcept C2776919658 @default.
• W4225517596 hasConcept C2778096610 @default.
• W4225517596 hasConcept C2778163477 @default.
• W4225517596 hasConcept C2778199505 @default.
• W4225517596 hasConcept C2778913445 @default.
• W4225517596 hasConcept C2780072125 @default.
• W4225517596 hasConcept C2780473172 @default.
• W4225517596 hasConcept C555293320 @default.
• W4225517596 hasConcept C71924100 @default.
• W4225517596 hasConceptScore W4225517596C126322002 @default.
• W4225517596 hasConceptScore W4225517596C134018914 @default.
• W4225517596 hasConceptScore W4225517596C139572402 @default.
• W4225517596 hasConceptScore W4225517596C2776175330 @default.
• W4225517596 hasConceptScore W4225517596C2776919658 @default.
• W4225517596 hasConceptScore W4225517596C2778096610 @default.
• W4225517596 hasConceptScore W4225517596C2778163477 @default.
• W4225517596 hasConceptScore W4225517596C2778199505 @default.
• W4225517596 hasConceptScore W4225517596C2778913445 @default.
• W4225517596 hasConceptScore W4225517596C2780072125 @default.
• W4225517596 hasConceptScore W4225517596C2780473172 @default.
• W4225517596 hasConceptScore W4225517596C555293320 @default.
• W4225517596 hasConceptScore W4225517596C71924100 @default.
• W4225517596 hasIssue "1" @default.
• W4225517596 hasLocation W42255175961 @default.
• W4225517596 hasLocation W42255175962 @default.
• W4225517596 hasLocation W42255175963 @default.

• next